Login / Signup

Introduction of a triphenylamine substituent on pyridyl rings as a springboard for a new appealing brightly luminescent 1,3-di-(2-pyridyl)benzene platinum(II) complex family.

Alessia ColomboGiulia De SoricellisFrancesco FagnaniClaudia DragonettiMassimo CocchiBertrand CarboniVéronique GuerchaisDaniele Marinotto
Published in: Dalton transactions (Cambridge, England : 2003) (2022)
The preparation and characterization of three new complexes, namely [Pt(1,3-bis(4-triphenylamine-pyridin-2-yl)-4,6-difluoro-benzene)Cl] ([PtL1Cl]), [Pt(1,3-bis(4-triphenylamine-pyridin-2-yl)-5-triphenylamine-benzene)Cl] ([PtL2Cl]), and [Pt(1,3-bis(4-triphenylamine-pyridin-2-yl)-5-mesityl-benzene)Cl] ([PtL3Cl]), is reported. All of them are highly luminescent in dilute deaerated dichloromethane solution ( Φ lum = 0.88-0.90, in the yellow-green region; the λ max,em in nm for the monomers are: 562, 561 and 549 for [PtL1Cl], [PtL2Cl] and [PtL3Cl], respectively).[PtL1Cl] is the most appealing, being characterized by a very long lifetime (103.9 μs) and displaying intense NIR emission in concentrated deaerated solution ( Φ lum = 0.66) with essentially no "contamination" by visible light < 600 nm. This complex allows the fabrication of both yellow-green and deep red/NIR OLEDs; OLED emissions are in the yellow-green (CIE = 0.38, 0.56) and deep red/NIR (CIE = 0.65, 0,34) regions, for [PtL1Cl] 8 wt% (with 11% ph/e EQE) and pure [PtL1Cl] (with 4.3% ph/e EQE), respectively.
Keyphrases
  • photodynamic therapy
  • risk assessment
  • quantum dots
  • sensitive detection
  • cystic fibrosis
  • pseudomonas aeruginosa
  • visible light